Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on ICON plc

Related ICLR
Cancer Genetics Inc. Announces a Partnership With ICON's Laboratory Services to Offer Comprehensive Oncology Laboratory Testing and Solutions
Jefferies Boosts Targets Across Pharmaceutical Service Stocks

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on ICON plc (NASDAQ: ICLR), and raised its price target from $29.00 to $32.00.

Jefferies noted, “ICON's investor day focused on the competitive differentiation and margin leverage that should come from recent technology and informatics investments. With robust backlog growth, management's revenue outlook for 2013 appears conservative. Nonetheless, efficiency improvements, utilization, and centralized support should drive considerable margin improvement, likely to the 10%+ level before 2013 is over.”

ICON plc closed on Tuesday at $27.66.

Latest Ratings for ICLR

Oct 2015Avondale PartnersInitiates Coverage onMarket Perform
Aug 2015Credit SuisseAssumesOutperform
Jul 2015KeyBancReiteratesOverweight

View More Analyst Ratings for ICLR
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (ICLR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters